Elsevier Science B.V. / The Boston Consulting Group / /
Continent
America / /
Country
United States / /
Currency
USD / / /
Event
Funding / FDA Phase / /
Facility
Duke University / University of Rochester / Tufts University / /
IndustryTerm
sector pharmaceutical industry investments / biopharmaceutical entities / niche pharmaceutical firms / molecule chemical entities / medical technologies / pharmaceutical sales / pharmaceuticals / pharmaceutical industry / ethical pharmaceuticals / pharmaceutical innovation / health care technologies / marketed new product / chemical entity / chemical / pharmaceutical firms / /
MedicalCondition
cancer / disease / targeted disease / AIDS / /
Organization
National Institute of Health / Graduate School / PhRMA / office of Technology / Department of Economics / US Food and Drug Administration / University of Rochester / Rochester / Tufts University / FDA’s Center for Drug Evaluation and Research / Congressional Budget Office / Tufts Center for the Study of Drug Development / Duke University / Durham / Medicare / /
Person
Ronald W. Hansen / Henry G. Grabowski / William E. Simon / / /
Position
representative / Corresponding author / /
Product
approved drug / drug / approved new drug / United States / /
ProvinceOrState
Massachusetts / /
PublishedMedium
Health Economics / /
Technology
drug discovery / antibodies / health care technologies / drug development / /
Journal of Health Economics[removed]–185 The price of innovation: new estimates of drug development costs Joseph A. DiMasi a,∗ , Ronald W. Hansen b , Henry G. Grabowski c a